Overactive Bladder - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 114 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Overactive Bladder - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Overactive Bladder - Pipeline Review, H1 2016', provides an overview of the Overactive Bladder pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Overactive Bladder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Overactive Bladder
- The report reviews pipeline therapeutics for Overactive Bladder by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Overactive Bladder therapeutics and enlists all their major and minor projects
- The report assesses Overactive Bladder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Overactive Bladder

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Overactive Bladder Overview 10
Therapeutics Development 11
Pipeline Products for Overactive Bladder - Overview 11
Pipeline Products for Overactive Bladder - Comparative Analysis 12
Overactive Bladder - Therapeutics under Development by Companies 13
Overactive Bladder - Therapeutics under Investigation by Universities/Institutes 15
Overactive Bladder - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Overactive Bladder - Products under Development by Companies 19
Overactive Bladder - Products under Investigation by Universities/Institutes 21
Overactive Bladder - Companies Involved in Therapeutics Development 22
Addex Therapeutics Ltd 22
Asahi Kasei Pharma Corp. 23
Astellas Pharma Inc. 24
Dompe Farmaceutici S.p.A. 25
FemmePharma Global Healthcare, Inc. 26
Hydra Biosciences, Inc. 27
Ion Channel Innovations, LLC 28
Jeil Pharmaceutical Co., Ltd. 29
Juniper Pharmaceuticals, Inc. 30
Lipella Pharmaceuticals, Inc. 31
Merck & Co., Inc. 32
Mezzion Pharma Co. Ltd. 33
MI.TO. Technology S.r.L. 34
Recordati S.p.A. 35
Sanofi 36
Sihuan Pharmaceutical Holdings Group Ltd. 37
Taris Biomedical LLC 38
TheraVida, Inc. 39
Toray Industries, Inc. 40
UroGen Pharmaceuticals, Ltd. 41
Overactive Bladder - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
(mirabegron + solifenacin succinate) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ADX-71441 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DA-8010 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
DFL-23448 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
fadanafil - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HC-067047 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
mirabegron ER - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
onabotulinumtoxin A - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
onabotulinumtoxinA SR - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
oxybutynin chloride - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
oxybutynin chloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
oxybutynin hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
pVAX-hSlo - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
REC-0438 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SAR-244181 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules to Block TRPV1 for Overactive Bladder - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
solabegron hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
solifenacin succinate - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
solifenacin succinate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
tacrolimus - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
TAR-302 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
THVD-201 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
THVD-202 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
udenafil - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
vibegron - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Overactive Bladder - Recent Pipeline Updates 89
Overactive Bladder - Dormant Projects 100
Overactive Bladder - Discontinued Products 105
Overactive Bladder - Product Development Milestones 107
Featured News & Press Releases 107
Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women 107
Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product 107
Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder 108
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 109
May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 110
Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial 110
Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder 111
Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder 111
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 112
May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 112
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables

Number of Products under Development for Overactive Bladder, H1 2016 11
Number of Products under Development for Overactive Bladder - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H1 2016 22
Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H1 2016 23
Overactive Bladder - Pipeline by Astellas Pharma Inc., H1 2016 24
Overactive Bladder - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 25
Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H1 2016 26
Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H1 2016 27
Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H1 2016 28
Overactive Bladder - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 29
Overactive Bladder - Pipeline by Juniper Pharmaceuticals, Inc., H1 2016 30
Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H1 2016 31
Overactive Bladder - Pipeline by Merck & Co., Inc., H1 2016 32
Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 33
Overactive Bladder - Pipeline by MI.TO. Technology S.r.L., H1 2016 34
Overactive Bladder - Pipeline by Recordati S.p.A., H1 2016 35
Overactive Bladder - Pipeline by Sanofi, H1 2016 36
Overactive Bladder - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 37
Overactive Bladder - Pipeline by Taris Biomedical LLC, H1 2016 38
Overactive Bladder - Pipeline by TheraVida, Inc., H1 2016 39
Overactive Bladder - Pipeline by Toray Industries, Inc., H1 2016 40
Overactive Bladder - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016 41
Assessment by Monotherapy Products, H1 2016 42
Assessment by Combination Products, H1 2016 43
Number of Products by Stage and Target, H1 2016 45
Number of Products by Stage and Mechanism of Action, H1 2016 47
Number of Products by Stage and Route of Administration, H1 2016 49
Number of Products by Stage and Molecule Type, H1 2016 51
Overactive Bladder Therapeutics - Recent Pipeline Updates, H1 2016 89
Overactive Bladder - Dormant Projects, H1 2016 100
Overactive Bladder - Dormant Projects (Contd..1), H1 2016 101
Overactive Bladder - Dormant Projects (Contd..2), H1 2016 102
Overactive Bladder - Dormant Projects (Contd..3), H1 2016 103
Overactive Bladder - Dormant Projects (Contd..4), H1 2016 104
Overactive Bladder - Discontinued Products, H1 2016 105
Overactive Bladder - Discontinued Products (Contd..1), H1 2016 106